Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c9c8e4d617114220527ae4048364bbc |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
filingDate |
2007-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48f8e6e36ee9b8548d23dcd67b40c2d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6e717f7e841cc8c7a9cc9027fd86699 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f54fcb74fae66af9b9c91d73aef5b67f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f65c28a783fac744303946af82f6ca99 |
publicationDate |
2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2010168012-A1 |
titleOfInvention |
Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture |
abstract |
The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10835593-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9850475-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015509501-A |
priorityDate |
2006-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |